• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Diabetes: Medtronic’s Resolute stent performs well in non-diabetics, too | Wall Street Beat

Diabetes: Medtronic’s Resolute stent performs well in non-diabetics, too | Wall Street Beat

May 25, 2012 By MassDevice staff

MassDevice.com Wall Street Beat

Medtronic (NYSE:MDT) touted new study results for its Resolute drug-eluting stents, the 1st with FDA indication for treatment of patients with diabetes.

In a 2-year follow up of patients with and without diabetes, the Resolute DES showed "consistently low event rates out to two years for both groups, despite the higher-risk nature of the diabetes patient population," according to a press release.

Rates of target lesion failure were 7.1% for patients without diabetes and 9.6% for patients with diabetes in a study pooling clinical trial results from 878 "standard risk" diabetes patients and 1,903 patients without diabetes.

Medtronic in February won FDA clearance for its Resolute Integrity DES to treat diabetic patients with coronary artery disease, which make up about ⅓ of the CAD population.

"They tend to have smaller and often tortuous arteries, longer lesions, diffuse disease and a higher rate of treatment failures including relatively high rates of repeat procedures and stent thrombosis," Medtronic told MassDevice at the time. "As a result, many of these patients have undergone open heart surgery."

MDT shares were down about 0.5% to $36.89 as of about 2:30 p.m. today.

 Tengion struggles, but may find refuge in Medtronic

Regenerative technology company Tengion (NSDQ:TNGN)
is running low on cash reserves and is on the edge of Nasdaq delisting, but a partnership with med-tech titan Medtronic (NYSE:MDT), a participant in past funding rounds, could help the company bolster its coffers.
Read more

 Uroplasty soars on 40% boost in Q4 sales
Minneapolis-based incontinence devices maker Uroplasty (NSDQ:UPI) posted a 39.4% increase in sales and cut losses in half during the 3 months ended March 31. The company beat analysts’ expectations by 4¢, posting losses of $573,000, or 3 cents per share.

Full year 2012 sales grew 49.1% to $20.6 million, and losses shrank 8.6% to $4.3 million.

UPI shares spiked 19.3% to $3.99 around 2:15 p.m. today.
Read more

 NeuroMetrix targets investors

Waltham, Mass.-based NeuroMetrix (NSDQ:NURO) hired IRG LLC to act as its investor relations agency, leading to speculation that the company may be on the auction block. The company said it would "implement a campaign targeting portfolio managers, analysts, and the retail community with the goal of increasing investor awareness of NeuroMetrix and its role in the fast-growing diabetes sector."

Read more

 Allscripts shareholders launch proxy war
One of Allscripts’ (NSDQ:MDRX) largest investors filed a lawsuit against the health IT services provider after CEO Glen Tullman refused to step down following the mass resignation of 3 board members and its chief financial officer when Tullman fired board chairman Phil Pead.

HealthCor Mgmt., which owns about 5% of Allscripts outstanding shares, sued in a Delaware court to block a company bylaw that would require that board nominations take place in January.
Read more

 Funding Roundup

  • Delcath prices $20M public offering at $1.50 per share
  • Becton Dickinson enters 5-year $1B credit agreement
  • Getinge raises $140M (SEK 1B) to refinance Atrium acquisition
  • Stereotaxis closes 2 funding rounds worth a collective $18.5M
  • Vibrynt gets halfway through a $5.5M funding round
  • Biostem U.S. announces $5M private placement financing agreement
  • Flowonix raises $25M for pain management drug pump
  • SPR Therapeutics wins $900k Ohio state loan
  • Cambridge Heart sells $2.5M in investment rights in 2 subscription agreements

 Analysts’ ups and downs

  • CareFusion (NYSE:CFN): CLSA upgrades from "outperform" rating to "buy" rating, maintains $30 price target
  • HeartWare International (NSDQ:HTWR): Cannacord Genuity reinstates "buy" rating
  • Hospira (NYSE:HSP): Leerink Swann maintains "market perform" rating, $36 price target
  • Siemens (NYSE:SI): Deutsche Bank upgrades to "buy" rating
  • Uroplasty (NSDQ:UPI): Craig-Hallum maintains "buy" rating and $4.50 price target; Dougherty & Co. raises price target from $5 to $5.50, maintains "buy" rating; JMP Securities raises to $6 price target and upgrades to "market outperform" rating

Filed Under: Drug-Eluting Stents, Funding Roundup, News Well, Wall Street Beat Tagged With: Allscripts, Clinical Trials, Deals Roundup, Neurometrix, Tengion Inc., Uroplasty Inc.

More recent news

  • Mount Sinai adopts Flosonics wearable ultrasound device
  • GE HealthCare launches next-gen intraoperative ultrasound
  • Philips launches new point-of-care ultrasound system
  • Medtronic to invest $50M in India Diabetes center
  • Corvia Medical raises $55M as it seeks FDA nod for atrial shunt

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy